NCT05111353View on ClinicalTrials.gov

Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

November 3, 2025

Study Completion Date

November 3, 2025

Conditions
Pancreas CancerPancreatic CancerCancer of the Pancreas
Interventions
BIOLOGICAL

Optimized neoantigen synthetic long peptide vaccine

Neoantigen vaccines will be provided on a patient-specific basis

BIOLOGICAL

Poly-ICLC

Poly-ICLC will be supplied by Oncovir, Inc.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Leidos
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Leidos

UNKNOWN

collaborator

UNICO Foundation

UNKNOWN

collaborator

The Foundation for Barnes-Jewish Hospital

OTHER

lead

Washington University School of Medicine

OTHER